RxDoctor Payments Data

Kathleen Raza

Acute Care · Bolingbrook, ILNPI 1497443915

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 75.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,581 and has fallen 89.4% since, to $485 in 2025. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,143in general payments, 2019–2025

Across 36 payments — averaging $142.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
  • Mallinckrodt Hospital Products Inc.$325
  • Bayer$274
  • Aurinia Pharma U.S., Inc.$145
  • GSK$125
  • Boehringer Ingelheim$125
  • plus $281 from 5 others

What the payments were for

  • Consulting fees$2,66452%
  • Travel & lodging$1,01520%
  • Food & beverage$1,46428%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,143 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.

See all acute care providers in Illinois

Medicare billing

Part B allowed, 2024
$22,844
Medicare patients
74
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Furosemide29$219
Losartan Potassium11$195
Carvedilol20$168

Paid to pharmacies, not to this prescriber.

Other acute care in Bolingbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →